Avances y líneas de investigación en el tratamiento y diagnóstico del tabaquismo Sanid. mil. 2017; 73 (1) 65 nicaltrials.gov/ct2/show/NCT02521662?term=electronic+cigarettes+AND+ smoking+cessation&rank=1 53. Evaluating the Efficacy of E-Cigarette Use for Smoking Cessation (E3) Trial. ClinicalTrials.Gov NCT02417467. Accedido 26 de agosto de 2015. Disponi-ble en: https://clinicaltrials.gov/ct2/show/NCT02417467?term=electronic+cig arettes+AND+smoking+cessation&rank=2 54. Spain-UK-Czech E-cigarette Study ((SUKCES)). ClinicalTrials.Gov NCT01842828. Accedido 26 de agosto de 2015. Disponible en: https://cli-nicaltrials. gov/ct2/show/NCT01842828?term=electronic+cigarettes+AND+ smoking+cessation&rank=10 55. Electronic Cigarettes or Nicotine Inhaler for Smoking Cessation. Clinical- Trials.Gov NCT02004171. Accedido 26 de agosto de 2015. Disponible en: https://clinicaltrials.gov/ct2/show/NCT02004171?term=electronic+cigarettes +AND+smoking+cessation&rank=3 56. E-Cigarettes Versus NRT Gum for Smoking Cessation. ClinicalTrials.Gov NCT01925781. Accedido 26 de agosto de 2015. Disponible en: https://cli-nicaltrials. gov/ct2/show/NCT01925781?term=electronic+cigarettes+AND+ smoking+cessation&rank=4 57. Trial to Evaluate the Efficacy of Simvastatin for Smoking Cessation (ADDICSTATINE). ClinicalTrials.Gov NCT02399709. Accedido 27 de agosto de 2015. Disponible en: https://clinicaltrials.gov/ct2/show/NCT0239 9709?term=simvastatin+AND+smoking+cessation&rank=1 58. Dinur-Klein L, Dannon P, Hadar A, Rosenberg O, Roth Y, Kotler M, et al. Smoking cessation induced by deep repetitive transcranial magnetic stimula-tion of the prefrontal and insular cortices: a prospective, randomized contro-lled trial. Biol Psychiatry. 2014; 76: 742 - 9. 59. Pripfl J, Tomova L, Riecansky I, Lamm C. Transcranial magnetic stimulation of the left dorsolateral prefrontal cortex decreases cue-induced nicotine cra-ving and EEG delta power. Brain Stimul. 2014; 7: 226 - 33. 60. rTMS for Smoking Cessation. ClinicalTrials.Gov NCT02401672. Accedido 27 de agosto de 2015. Disponible en: https://clinicaltrials.gov/ct2/show/NCT 02401672?term=rTMS+AND+smoking+cessation&rank=2 61. A Mindfulness Based Application for Smoking Cessation (MBSC). . Clinical- Trials.Gov NCT01982109. Accedido 29 de agosto de 2015. Disponible en: https://clinicaltrials.gov/ct2/show/NCT01982110?term=mindfulness+AND+ smoking+cessation&rank=1 62. Pentel PR, LeSage MG. New directions in nicotine vaccine design and use. Adv Pharmacol. 2014; 69: 553-80. 63. Mamoun M, Bergen AW, Shieh J, Wiggins A, Brody AL. Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date. CNS Drugs. 2015; 29: 359 - 69. 64. Jiménez-Ruiz CA, Pascual Lledó JF, Cicero Guerrero A, Mayayo Ulibarri M, Cristóbal Fernández M, Perera López L. Searching for phenotypes in smoking cessation treatment. Int J Clin Pract. 2014; 68: 1530-9. 65. King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV et al. Smo-king cessation pharmacogenetics: analysis of varenicline and bupropion in pla-cebo- controlled clinical trials. Neuropsychopharmacology. 2012; 37: 641-50. 66. Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Be-nowitz NL, et al. Association of nicotine metabolite ratio and CYP2A6 ge-notype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther. 2009; 85: 635 – 43. 67. Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin Pharmacol Ther. 2010; 87: 553 – 7. 68. Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smo-king cessation. Clin Pharmacol Ther. 2006; 79: 600 – 8. 69. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transder-mal nicotine: a validation study. Pharmacol Biochem Behav. 2009; 92: 6 – 11. 70. Lerman C, Schnoll RA, Hawk LW Jr, Cinciripini P, George TP, Wileyto EP, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2015; 3: 131 – 8. 71. Allenby CE, Boylan KA, Lerman C, Falcone M. Precision Medicine for To-bacco Dependence: Development and Validation of the Nicotine Metabolite Ratio. J Neuroimmune Pharmacol. 2016 Feb 12. Epub ahead of print. DOI: 10.1007/s11481-016-9656-y. 72. Tang DW, Hello B, Mroziewicz M, Fellows LK, Tyndale RF, Dagher A. Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI. Neuroimage. 2012; 60: 2136-43 73. Falcone M, Cao W, Bernardo L, Tyndale RF, Loughead J, Lerman C. Brain Responses to Smoking Cues Differ Based on Nicotine Metabolism Rate. Biol Psychiatry. 2016; 80: 190-7
REVISTA DE SANIDAD FAS ENEMAR 2017
To see the actual publication please follow the link above